AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Conscious Sedation
Conditions
Conscious Sedation
Trial Timeline
Mar 1, 2006 → Oct 1, 2006
NCT ID
NCT00261599About AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI is a phase 3 stage product being developed by Eisai for Conscious Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT00261599. Target conditions include Conscious Sedation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00261599 | Phase 3 | Completed |
Competing Products
2 competing products in Conscious Sedation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dexmedetomidine + Propofol | Pfizer | Approved | 84 |
| Dexmedetomidine | Orion Corporation | Phase 3 | 74 |